Evidence map›Paper›PMID 35171314›Full record

ArticleDer Pathologe2022

[Histopathological evaluation of nonalcoholic fatty liver disease : Automated evaluation of liver biopsies].

Nada Abedin, Andrea Tannapfel, Peter J Wild, Iris Tischoff

Abstract read
PubMed Publisher
In one paragraph

Article in Der Pathologe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nada AbedinMedizinische Klinik 1, Universitätsklinikum Frankfurt, Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland. nada.abedin@kgu.de.
Andrea TannapfelInstitut für Pathologie, Ruhr-Universität Bochum, Bochum, Deutschland.
Peter J WildDr. Senckenbergisches Institut für Pathologie, Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt am Main, Deutschland.
Iris TischoffInstitut für Pathologie, Ruhr-Universität Bochum, Bochum, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent chronic liver diseases with a rising incidence in industrial countries. This is accompanied by an increased prevalence for NAFLD-associated liver cirrhosis and an increased risk for developing hepatocellular carcinoma. The current gold standard in the diagnostics is a liver biopsy. The histopathological evaluation is performed through semiquantitative scoring. To optimize the standardization and quantification of the existing scoring systems, in the coming years procedures with artificial intelligence, such as deep learning models could be used. Fields of application could be the supplementation of conventional histopathological diagnostics, the identification of new predictive parameters for estimating the prognosis and the prediction of a possible response to treatment.

Indexed as

Liver NeoplasmsNon-alcoholic Fatty Liver DiseaseArtificial IntelligenceBiopsyHumansLiverLiver CirrhosisArtificial intelligenceBiopsyDeep learningScoring systemsSteatohepatitis

Identifiers

PMID35171314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.